Shareholders of Chinese firms eye Hong Kong for family offices: asset manager

A signal problem at London Waterloo caused train cancellations earlier today. While the issue has now been resolved, Network Rail is still advising passengers to avoid travel for the time being as services get back on track.

Editor’s Note: Even though the technical glitch is fixed, delays and cancellations will likely ripple through the network for a while—meaning commuters should brace for a messy journey or hold off if they can. It’s another headache for London’s rail users, who’ve dealt with plenty of disruptions lately.

Porsche's CEO is sounding the alarm, saying the luxury carmaker's current business model is broken in today's shifting global landscape—think post-Trump trade tensions and China's evolving market. The company, heavily dependent on exports, is now scrambling to slash costs, including cutting over 10% of its German workforce (that's around 3,700 jobs). It's a stark admission that even high-end brands aren't immune to economic headwinds.

Editor’s Note: When a premium player like Porsche starts talking about "crisis" and mass layoffs, it’s a sign that even the auto industry’s glitziest names are feeling the squeeze. This isn’t just about belt-tightening—it hints at deeper challenges, from trade wars to slowing demand in key markets like China. If Porsche’s struggling to adapt, other carmakers should be paying attention.

Verizon is still losing postpaid phone subscribers—those coveted customers who pay monthly bills—thanks to aggressive deals from competitors. However, there’s a silver lining: the company raised its full-year profit forecast, suggesting cost-cutting or other strategies might be offsetting the subscriber bleed.

Editor’s Note: Losing postpaid subscribers isn’t great—it’s the bread and butter of wireless carriers—but Verizon’s improved outlook hints they’re finding ways to stay profitable despite the squeeze. For consumers, this means the promo wars aren’t slowing down, so better deals might still be up for grabs. For investors, it’s a mixed bag: growth is shaky, but the bottom line might hold.

India's infrastructure sector—which includes key industries like coal, steel, and electricity—saw its fastest growth in three months this June. That’s a solid sign that the country’s industrial backbone is picking up steam, even if some sectors like cement and crude oil are still lagging behind.

Editor’s Note: Infrastructure is like the economy’s pulse—when it’s strong, it usually means more jobs, better supply chains, and overall growth. This uptick suggests India’s recovery is gaining momentum, though uneven performance in some areas means there’s still work to do. For everyday folks, it could mean more stability (and maybe more projects in their towns), but don’t expect overnight changes.

The Guggenheim investment firm is sticking with its "Buy" recommendation for Arcutis Biotherapeutics' stock, citing steady growth in prescriptions for the company's treatments. Essentially, they see enough momentum in patient demand to keep betting on the stock.

Editor’s Note: When a major firm like Guggenheim doubles down on a "Buy" rating, it signals confidence in the company’s commercial traction—in this case, Arcutis’ ability to get its therapies into doctors’ hands. For investors, it’s a nudge that the biotech’s pipeline might be gaining real-world traction, which could mean upside ahead. For the broader sector, it’s a reminder that prescription trends often drive Wall Street’s love (or lack thereof) for pharma stocks.